Enzastaurin
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Follicular
Conditions
Lymphoma, Follicular
Trial Timeline
May 1, 2007 → Dec 1, 2014
NCT ID
NCT00475644About Enzastaurin
Enzastaurin is a phase 2 stage product being developed by Eli Lilly for Lymphoma, Follicular. The current trial status is completed. This product is registered under clinical trial identifier NCT00475644. Target conditions include Lymphoma, Follicular.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma, Follicular were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01432951 | Phase 1 | Completed |
| NCT00744991 | Phase 2 | Completed |
| NCT00718419 | Phase 2 | Completed |
| NCT00542919 | Phase 2 | Completed |
| NCT00475644 | Phase 2 | Completed |
| NCT00452257 | Phase 1 | Completed |
| NCT00420381 | Phase 2 | Completed |
| NCT00428714 | Phase 2 | Completed |
| NCT00309140 | Phase 2 | Completed |
| NCT00088205 | Phase 2 | Completed |
| NCT00190723 | Phase 2 | Completed |
Competing Products
20 competing products in Lymphoma, Follicular